Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI
Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid...
Spremljeno u:
Glavni autori: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Jezik: | engleski |
Izdano: |
2020
|
Online pristup: | https://doi.org/10.1148/radiol.2020192018 |
Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Budi prvi tko komentira!